Immune cells may contribute to pancreatic cancer development, yet studies haven’t thoroughly explored this connection prospectively.
A nested case-control study within the EPIC project analyzed immune cell counts in 502 individuals with pancreatic cancer compared to matched controls.
While individual immune cell counts did not show a significant relationship with cancer risk, higher levels of regulatory T cells and lower levels of CD8 cells were linked to increased risk shortly after diagnosis, suggesting potential late-stage tumor development.